This plenary session will address the recent FDA approval of a new medication for HIV biomedical prevention of HIV- 1 for specific populations at sexual risk for HIV. This sent shockwaves through the HIV workforce and its advocacy base due to a specific exclusion for “individuals at risk from receptive vaginal sex.” Representatives of the Atlanta Women PrEP leaders group will lead a discussion around the implications of excluding cisgender women, specifically Black women, from the benefit of a biomedical prevention strategy in a time where black women comprise nearly 27% of diagnoses among Black/African-Americans, an alarming 60% of all diagnoses among women, and 52% of diagnoses globally. How does this exclusion contribute to the conversation of inequity, social justice, and ending the HIV epidemic in this country and abroad given this decision and lack of action? This convened panel of representational experts will attempt to provide a response to this critical public health question.
The session will conclude with a memorial to honor and remember the transgender women of color who have been murdered this year as well as the other transgender family members who perished too soon.